FIND prices for GenoType® MTBDRplus and Country List

Enhancement of diagnostic capacity for TB and MDR-TB is urgently needed to scale-up access to care and treatment of MDR-TB. To help meet this challenge, FIND has collaborated in the development and evaluation of new TB diagnostic tools, including TB liquid culture and DST, rapid species identification, and line probe assay. WHO has officially endorsed the use of these technologies based on the thorough evaluation of the evidence of their effectiveness under actual program conditions. As part of its role in the development and evaluation process of these tools, FIND has successfully negotiated with three of the manufacturing partners to obtain significant price reductions in order to facilitate access to these diagnostic technologies. These discounts average 50% on diagnostic instruments, and 75% on reagents, and are available to high TB burden countries that wish to procure TB diagnostics for use in the public and non-profit health care sectors, and who procure these tools with funding from the government, UNITAID, or the Global Fund. Furthermore, the FIND-negotiated agreements contain provisions for further discounts as procurement volumes of reagents increase. As these become available, FIND shall communicate the new prices to the TB community. 

Current FIND-negotiated prices, along with the list of countries eligible for the discounts, as negotiated by FIND with HAIN Lifescience are listed below: 

These prices are FOB at the manufacturer loading bay. In all cases it is recommended that the local HAIN representative is contacted with respect to additional costs beyond the FOB cost which may include one or more of the following:

Fully landed

Additional transport and shipping (international and local costs), insurance, clearing, customs duties and local taxes, where applicable, as well as the local representative costs. An example is for India, China and Latin America, the end user price is €7.50 (approx US$9.96) which includes all the above and ongoing training, service and local support.

A further element which should be considered is the annual volume of test usage and price versus volume should be discussed with the HAIN representative in the country. For example for India, China and Latin America the representative is the local bioMérieux office and in South Africa it is Hain Lifescience SA (PTY) Ltd.
 

Implementation

Where required from the local HAIN representative (the local company representative can give precise details);

• Training costs
• Costs of service contracts for the Instrumentation (estimated usually at 15% of the FOB instrument price). The Instrumentation comes with a 1 year warranty, so a service contract should be calculated for year 2 onwards

Infrastructure

• Laboratory renovation
• Electrical supply, possibly including a backup generator

In addition to these costs, additional investment that is related more generally to establishing fully functional TB laboratory networks should be considered, including;

• Specimen transport costs
• Other essential supplies (gloves, respirators, lab gowns and lab coats)
• Other needed equipment (refrigerated safety centrifuges, freezers, pipettes, etc.)
• Costs related to Quality Assurance
• Laboratory management information system-related costs (LMIS), for inventory management; recording and reporting results.

These should also be taken into consideration when developing budgets and work plans (Figure 1). Guidance is available through the Global Laboratory Initiative and WHO for these areas. 

Countries for which FIND-negotiated prices and the products are available today

* Additions to this country list can be addressed on a case-by-case basis by FIND with the manufacturing partners.